StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
562 Study Matches

SPICE UP MyPlate - Strategy for Promoting Intake of Delicious Healthful Dietary Patterns Based on MyPlate: A Pilot Study

The aim is to conduct a pilot study to assess the feasibility, acceptability and potential effectiveness of culinary focused nutrition education to promote increased adherence to the Dietary Guidelines for Americans compared to standard low-intensity care.

You will be asked to attend two fasting clinic visits. At these visits paperwork will be completed, measures of weight, height, waist circumference, and vascular health will be taken. A blood draw will also be taken. If you are randomized to the culinary focused nutrition education group, you will be asked to attend weekly 1-hour face-to-face group education sessions during the first month of the study. For months 2 and 3 face-to-face sessions will be held bi-weekly for 1 hour. You will also receive emails containing videos and other resources. If you are in the standard nutrition education group, you will receive nutrition education via written study material and a phone application (app) and you will not have to attend education visits.

250

Yes
 

Kristina Petersen
Kayla Tate - at DCHLab@psu.edu
Nutritional Sciences (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00022406
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 31-59
Involved in meal cooking at home and consumes a home cooked meal ≥ 1 time per week
Non-smoking

Exclusion Criteria:
A member of the household is already enrolled
Received nutrition education for a medical condition within the past 6 months
Currently following a weight loss diet
Lost ≥ 10% body weight in the past 6 months
Unstable medical conditions requiring active intervention
Food & Nutrition
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

COVID-19: Implications for Family Meals

The purpose of this study is to gather information about family meals, what they look like, and how they have changed over time since the COVID-19 pandemic. Participants will complete a confidential online survey last approximately 10-15 minutes.

No
 

Hannah Mudrick
Hannah Mudrick - at hxm99@psu.edu or 717-948-6404
Behavioral Sciences and Education (HARRISBURG)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00015422
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults age 18 and older
Adults who live in a household with a child under the age of 18
Adult who are fluent in English
Individuals who can read and respond to written closed and open-ended survey questions electronically
Individuals who live in the United States

Exclusion Criteria:
Individuals under the age of 18
Individuals who do not reside in a household with a child under the age of 18
Individuals who are not fluent in English
Individuals with poor reading comprehension or are otherwise limited in their ability to read and respond to survey questions.
Individuals who do not currently live in the United States
Food & Nutrition
I'm interested
Share via email

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC) (PSCI 18-112)

This study is a comparison of disease-free survival of patients with high-risk cutaneous squamous cell carcinoma (CSCC) when treated with a medication (cemiplimab) versus those treated with placebo after already having surgery and radiation therapy.

The study is conducted in 2 parts. Part 1 consists of a screening period, treatment period and a completion period including a period of long term follow up. During part 1, you will be asked to answer questions about your health, participate in a physical examination that includes vital signs,height and weight, have testing done including an electrocardiogram, blood draws, urine sampling, pregnancy test, biopsy, and medical imaging. Part 2 consists of an additional screening period, treatment period and an end of treatment period.

70.00 per visit

Yes
 

Joseph Drabick
Irina Geier - at igeier@pennstatehealth.psu.edu
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03969004
STUDY00013965
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
High risk cutaneous squamous cell carcinoma
Post resection and curative intent post-operative Radiation Therapy within 2 to 6 weeks of randomization
Adequate hepatic, renal, and bone marrow function as defined in the protocol

Exclusion Criteria:
Patients with blood cancer (hematologic malignancies) or other malignancies
Squamous cell carcinomas (SCCs) arising in non-cutaneous sites as defined in the protocol
Significant autoimmune disease that required treatment with systemic immunosuppressive treatments (including corticosteroids)
Has had prior systemic anti-cancer immunotherapy for cutaneous squamous cell carcinoma
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Global, Open-Label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

This is an open-label drug study of SerpinPC (a subcutaneously administered drug) for patients with severe hemophilia A or moderately severe to severe Hemophilia B. The study consists of 3 parts after an observation phase of 12-24 weeks: 24 week justification phase, 24 week confirmatory phase & 24 week extension phase.

This is a subcutaneous drug treatment clinical trial with an observation period of up to 24 weeks, pre-dosing/dosing period of 8 visits on site or phone calls & an extension period of 6 visits.

$75.00 travel reimbursement per visit

Yes
 

M. Elaine Eyster
Cynthia Campbell-Baird - at cbaird@pennstatehealth.psu.edu or 717-531-5777
Medicine: Hematology and Medical Oncology (HERSHEY)
 

Male
All
This study is NOT accepting healthy volunteers
NCT05789524
STUDY00022327
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Males ages >12 & <65 with severe hemophilia A or moderately severe to severe hemophilia B
Subjects include prophylactic dosing or on-demand dosing for factor replacement
Adequate laboratory functions

Exclusion Criteria:
Subjects with a previous factorVIII or factor IX inhibitor
Previous deep vein thrombosis, pulmonary embolism, MI or stroke.
Uncontrolled hypertension, active cancer (except basal cell)
Weight > 150kg (330 lbs.) or BMI > 40kg/m2
Blood Disorders
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Student Experience in New Class Modes during Covid-19

This is a survey study that will examine how the new instruction modes during COVID-19 have impacted undergraduate education experience. Participants will be asked to complete a survey to give feedback and comments on their classes. The survey will take 15 - 20 minutes.

No
 

Chuhao Wu
Chuhao Wu - at cjw6297@psu.edu or 765-772-8073
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00016364
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or order
An active undergraduate student at University Park campus
Enrolled for as least one class
Can read instruction materials written in English

Exclusion Criteria:
NA
Education
I'm interested
Share via email

Understanding the relationship of financial difficulties and mental health among a sample of American Undergraduate Students.

Aim is to explore how student's financial status and experiences influence their emotional, psychological, and social well being while being in university.

Participants, upon their consent, will be required to fill a Qualtrics survey on their personal laptop or computer.

No
 

Saeed Abdullah
Eleazar Bilewu - at ejb5857@psu.edu or 443-707-6474
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00022016
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
U.S Citizen
18 years or older
Penn State Undergraduate Student
Fluent in English

Exclusion Criteria:
Under 18 years old
Non U.S Citizen
Non Penn State Undergraduate Student
Education, Mental & Behavioral Health
Survey(s)
I'm interested
Share via email

Dynamic Assessment of English Vocabulary

Better understand and improving Chinese English learners' vocabulary development

•Complete seven sessions, which may take approximately 20-30 minutes of your time per session.•Read several English short texts and identify meanings of target words.•Possibly participate in a virtual interview that will be scheduled at your convenience.

No
 

Yuwei Xia
Yuwei Xia - at yxx5304@psu.edu
Division of Graduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023081
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Of Chinese origin or descent
Adult English learners
Currently enrolled in a college or university

Exclusion Criteria:
English as native language
Education
Not applicable
I'm interested
Share via email

A Survey to Estimate the Socio-Economic Impact of the Novel Corona Virus (COVID-19) Pandemic

We are experiencing global outbreak of coronavirus (COVID-19) recently. Millions of people are suffering and dying every day, in spite of putting our best efforts. We are doing this survey to understand people’s reaction to this situation. The survey will ask about your knowledge, practices and worries. Your response will help us to understand how to better control these situations. Your feedback is highly important to us, as we need to find out the best way to stop the disease from spreading and killing thousands of lives, and to reduce the stress among the population.

No
 

Pritish Mondal
Pritish Mondal - at pmondal@pennstatehealth.psu.edu or 717-897-0652
Pediatrics: Allergy and Immunology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00015136
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
General population
Adult

Exclusion Criteria:
Age below 18 years
Mentally impaired
Participants from Europe or European Union (EU)
Infectious Diseases & Immune System, Prevention, Lung Disease & Asthma
I'm interested
Share via email

How do cues from the environment affect sound perception?

This study is about investigating how certain elements of urbanconfiguration affects people's subjective perception of noise in urbanenvironments.This section of the study assesses participants' subjective reactions tonoise intensity when the tree density changes in various spaces.

Yes
 

Sohail Sadroleslami
Sohail Sadroleslami - at sbs5622@psu.edu or 814-883-7773
Architecture (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00014527
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age: 18 -24
Gender: all
no visual or hearing impairments

Exclusion Criteria:
no visual or hearing impairments
Vision & Eyes
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Effects of acid sensing ion channels blockade on the exercise pressor reflex following ischemia-reperfusion stress in healthy individuals

The purpose of this voluntary research study is to test if the drug amiloride can decrease blood pressure during exercise.

This project includes 3 visits to the research lab. Each visit last approximately 3.5-4 hours (~11-12 hours altogether). In each visit, you will be asked to perform foot exercise before and after a blood pressure cuff on your leg was inflated. You will also be asked to take pills prior to visit 2 and 3. One of these pills will be a drug called amiloride (10mg), which was traditionally used to lower blood pressure. The other pill will be a placebo (no active medication).

You will receive $25 per hour for your participation in this research study

Yes
 

Jian Cui
Cheryl Blaha - at cblaha@pennstatehealth.psu.edu or 717-531-1605
Heart and Vascular Institute (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00021886
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Men and women of any race or ethnicity
21-40 years of age
Healthy (absence of any active or chronic disease)

Exclusion Criteria:
Are not between 21-40 years old
Pregnant or nursing women
Have a major disease (heart, lungs, kidney, diabetes, cancer)
current smoker
High blood pressure
Heart & Vascular
Prefer not to display
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Understanding the Experiences of College Students of Color with Psychiatric Disabilities

The purpose of this study is to develop a better understanding of the lived experiences of college students of color with psychiatric disabilities, particularly related to the formation of racial identity, disability identity, and the impact of perceived discrimination.

Yes
 

Amber O'Shea
Amber O'Shea - at amo5208@psu.edu or 814-867-5721
Educational Psychology, Counseling and Special Education (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00014142
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Currently enrolled as a college student
18 years of age or older
Capable of providing informed consent
Diagnosis of a psychiatric disability
Identify as a person of color

Exclusion Criteria:
Adults unable to provide legal consent
Individuals who are not yet legal adults
Prisoners
Unable to speak/read English Language at time of interview
Addiction & Substance Abuse, Education, Mental & Behavioral Health
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide (NRG-GU008) (PSCI# 20-087)

The purpose of this study is to compare the use of hormone therapy and radiation therapy (usual treatment) to the use of apalutamide and abiraterone acetate with prednisone plus the usual treatment. The addition of apalutamide and abiraterone acetate with prednisone to the usual treatment could stabilize your cancer and prevent it from spreading. But it could also cause side effects, which are described in the risks section below.This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study approach increases the time without prostate cancer spreading compared to the usual approach. The study drugs, apalutamide and abiraterone acetate with prednisone, are already approved by the FDA for use in prostate cancer. But, most of the time abiraterone acetate with prednisone is not used until hormone drugs stop working and apalutamide is not used until hormone drugs stop working and after prostate cancer has spread. There will be about 586 people taking part in this study.

The purpose of this study is to compare the use of hormone therapy and radiation therapy (usual treatment) to the use of apalutamide and abiraterone acetate with prednisone plus the usual treatment. The addition of apalutamide and abiraterone acetate with prednisone to the usual treatment could stabilize your cancer and prevent it from spreading. But it could also cause side effects, which are described in the risks section below.This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study approach increases the time without prostate cancer spreading compared to the usual approach.The study drugs, apalutamide and abiraterone acetate with prednisone, are already approved by the FDA for use in prostate cancer. But, most of the time abiraterone acetate with prednisone is not used until hormone drugs stop working and apalutamide is not used until hormone drugs stop working and after prostate cancer has spread. There will be about 586 people taking part in this study.

Yes
 

Joseph Miccio
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Radiation Oncology (HERSHEY)
 

Male
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04134260
SITE00000791
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pathologically (histologically) proven diagnosis of prostate adenocarcinoma
History/physical examination within 90 days prior to registration
ECOG Performance Status of 0-1 within 90 days prior to registration
Any T-stage is eligible (AJCC 8th ed)
Adequate hepatic function within 90 days prior to registration

Exclusion Criteria:
Didanosine (DDI) antiretroviral therapy is not permitted
Seizure or known condition that may pre-dispose to seizure
Severe or unstable angina, myocardial infarction, arterial or venous thromboembolic events within 6 months prior to registration
Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg prednisone/prednisolone once daily
Patients with inflammatory bowel disease.
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

The effects of creatine supplementation on neurocognitive function of college students of differing levels and types of physical activity

This study design is a survey that collects information about students' active level and supplement use, with an emphasis on creatine. The difference between contact and non-contact athletes will be examined, in addition to people who are considered inactive/low activity. This will help provide information of how physical activity related supplementation use affects cognition in different populations, with varying amounts of neurotrauma.

All participants will complete a digital survey that provides information about their dietary supplementation and physical activity habits. As part of the survey, participants will be allowed to indicate their interest and availability to come to a laboratory setting to complete a brief batter of neurocognitive tests.

Yes
 

Semyon Slobounov
Bogdan Ivanov - at bmi5063@psu.edu or 617-327-4064
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023261
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older

Exclusion Criteria:
Under 18 years of age
Has had concussion in last 3 months
Food & Nutrition, Sports Medicine
Survey(s)
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Sex and race differences in exercise pressor reflex under blood flow restriction condition

The purpose of this voluntary research study is to test the effects of exercise on reduction in blood flow to exercising muscle.

You will be asked to participate in one visit to perform handgrip exercise and foot exercises with, and without a blood pressure cuff inflated on your arm and leg. Various physiological measurements will be recorded during this time including microneurography, blood pressure, heart rate, blood flow and muscle oxygenation.

You will receive $25 per hour for your participation in this research study

Yes
 

Jian Cui
Cheryl Blaha - at cblaha@pennstatehealth.psu.edu or 717-531-1605
Heart and Vascular Institute (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023505
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Males and Females 21-80 years of age
All races and ethnicities welcome
Are fluent in written and spoken English
Healthy status as defined by history and physical
blood pressure that is within a safe range (<150/100)

Exclusion Criteria:
less than 21 years of age or greater than 80 years of age
Pregnant or nursing woman
Current smoker
Any chronic diseases (heart, lung, neuromuscular disease or diabetes)
High blood pressure
Heart & Vascular
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Exploratory Trial of Ruxolitinib 1.5% Cream for Early Stage Hidradenitis Suppurativa

Explore all stages of Hidradenitis Suppurativa with a topical medication.

There will be 7 in-person visits and 1 follow-up phone call over a 33 week period. Over the course of the study, the following study procedures will take place: medical history and medication history collection, ECG, lab tests (both blood and urine), photography, skin exams, physical exams, questionnaires, and skin biopsies.

Up to $350

Yes
 

Andrea Zaenglein
Amy Longenecker - at alongenecker@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04414514
STUDY00016042
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must have diagnosis of HS for at least 3 months (90 days)
Must have active HS in at least 1 area
Must have negative TB screening assessment
Certain medications can be continued if on stable dose; study coordinator will discuss further.

Exclusion Criteria:
Any other active skin disease or condition that may interfere with assessment of HS
Pregnant (or considering becoming pregnant) or lactating females
Does not have reliable internet access for weekly electronic surveys
Skin Conditions
Prefer not to display
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Implementation of a Transcutaneous CO2 Monitoring (ITCOM) Study in ALS

Amyotrophic lateral sclerosis (ALS) leads to respiratory failure due to chronic hypoventilation. The gold standard for measuring hypoventilationrequires an arterial blood gas, which is impractical in the outpatient setting due to invasiveness, pain, and need for specialized equipment. Recently, the Penn State Health Hershey ALS Clinic has implemented transcutaneous CO2 (TCO2) monitoring as standard of care clinical assessment. The overall goals of this study are to gather critical preliminary data for stakeholder-driven refinement of a TCO2 monitoring protocol within a busy ALS clinic and identify how TCO2 may enhance our understanding of standard respiratory measurements.

Participants will complete a survey related to their experience having their CO2 reading performed in the ALS Clinic.

$20 will be paid for every survey completed, for a maximum possible payment of $80 per person.

Yes
 

Andrew Geronimo
Cristie Crawford - at ccrawford5@pennstatehealth.psu.edu
Neurosurgery (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00022352
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of ALS based on Gold Coast Criteria.
18 years of age or older.
Seated forced vital capacity (FVC) of less than 100% predicted normal.

Exclusion Criteria:
Inability to perform FVC due to severe bulbar weakness
Use of any type of non-invasive ventilation, except in the case of continuous positive airway pressure (CPAP) for obstructive sleep apnea
Use of diaphragm pacer
Use of a tracheostomy
In hospice or in active transition to hospice
Neurology
Survey(s)
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Young Children’s Representations of Parent-Child Negotiation

The goal of this study is to learn how young children think and tell stories about challenges between parents and children. Children will play games and tell stories using toys while caregivers fill out surveys and talk to researchers. This will occur twice, about 6 months apart. Qualities of children's stories, their language and regulation skills, demographic information about children and caregivers, and parenting behaviors will be examined.

Yes
 

Hannah Mudrick
Hannah Mudrick - at hxm99@psu.edu or 717-948-6404
Behavioral Sciences and Education (HARRISBURG)
 

All
All
This study is also accepting healthy volunteers
STUDY00007452
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Children between the ages of 5 and 7
At least one caregiver of a child between ages 5 and 7
English-speaking
Middle income
Caregiver at least 18 years old

Exclusion Criteria:
Caregivers that are not fluent in English
Children that are not fluent in English
Children who are unable to tell stories with a researcher due to developmental disability or language delay
Children who are younger than 5 or older than 7
Low or high income
Education, Mental & Behavioral Health
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Harrisburg, PA ,

The HEALthy Brain and Child Development Study (HBCD)

This multi-site consortium research study, entitled the HEALthy Brain and Child Development (HBCD) study, willprospectively examine human brain, cognitive, behavioral, social, and emotional development beginning prenatallythrough age 10 years. The study will determine the short- and long-term impacts of a variety of potentially harmfulas well as protective environmental factors. These include prenatal substance use, mental health, stress,sociodemographics, biological and genetic factors, and parent/child interaction. The overall goal of this study is tounderstand the neurodevelopmental trajectories of children growing up in diverse environments. A sample of~7,500 pregnant women will be recruited from 25 sites across the U.S. and they and their liveborn children will befollowed for 10 years.

If you agree for you and your child to participate, we will ask you to take part in completing visits from pregnancy through the first 10 years of your child’s life. These visits will take place both in-person and remotely. The length of visits will vary and may last between approximately one to nine hours per visit (which can be broken up into multiple visits). Over the first four years of the study, all study visits will require about 33-37 hours total. This will include interviews, questionnaires and other tests about yourself and your child. We will ask you and your child to wear small devices for a few days to measure heart rate and or movement. We will ask you and your child to provide some biological samples. Because this study is looking at how a child’s brain develops in the first years of life, we will ask that you allow your child to have brain scans and other measures of how your child’s brain is developing. This study is being offered in both State College, PA at the University Park campus and in Hershey, PA at the College of Medicine campus. You may choose to complete this study at either site.

$1,350

Yes
 

Koraly Perez-Edgar
hbcd@psu.edu;hbcd@pennstatehealth.psu.edu 814-826-1422
Psychology (UNIVERSITY PARK)
 

All
All
This study is also accepting healthy volunteers
SITE00001129
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pregnant or recently gave birth
Speaks English or Spanish

Exclusion Criteria:
Is not pregnant or does not have newborn
Does not speak English or Spanish
Children's Health, Pregnancy & Infertility, Women's Health
Not applicable
I'm interested
Share via email
Show 2 locations

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,
State College, PA ,

Exploring Parental Influence in Youth Disability Sport Participation

We are conducting an online survey study for parents of children with disabilities that explores their perceptions of participation in disability sport within their communities.

No
 

Courtney Jasiulevicius
Courtney Jasiulevicius - at cmj5308@psu.edu or 813-846-4145
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00007905
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
has a child with a physical disability or sensory disability
has a child that is enrolled in a disability or adapted sport program
has a child between the ages of 10 and 17

Exclusion Criteria:
does not have a child with a physical or sensory disability
does not have a child with a disability between the ages of 10 and 17
does not have a child that plays a disability or adapted sport
I'm interested
Share via email

Testing the Risk Preferences of Engineering Students under Conditions of Limited Information, Sleep, Optimism, and Time Constraints

This is a study that will examine how engineers make decisions under certain conditions and the factors that drive these decisions. The game will be used to simulate different engineering scenarios. All you need to do is play an online game with 3 different scenarios and choose what you feel is the better design based on the available information.

No
 

Uzoezi Isaac-Onwah
Uzoezi Isaac-Onwah - at uji5002@psu.edu
Energy and Mineral Engineering (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00013678
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Undergraduate engineering students
Over 18 years old
Speaks English

Exclusion Criteria:
Under 18
Graduate Students
Non-Engineering Majors
Education, Sleep Management
I'm interested
Share via email

A Second Intermediate Expanded Access Protocol for AmyotrophicLateral Sclerosis with CNM-Au8

The main purpose of this research study is to provide access to the investigational product, CNM-Au8 at a dose of 30mg per day, to up to 300 people living with ALS. The study wants to find out if CNM-Au8 is safe to take without causing too many side effects and can help people with ALS.

Participants will have a visit to see if they qualify to participate. Following this visit, they will return to the clinic for visits every 12 weeks and these visits will continue in 48-week periods until the treatment plan is discontinued. Participants will have one last visit 4 weeks after their last dose of the investigational medicine. 

Yes
 

Zachary Simmons
nervemuscle@pennstatehealth.psu.edu 717-531-8257
Neurology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05281484
SITE00001330
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
ior participation in the HEALEY Platform ALS trial (Regimen C) Open Label Extension (NCT04414345) will be considered an automatic inclusion.
Able to understand and give written informed consent.
Male or female participants aged 18 years or greater (inclusive) at the time of ALS diagnosis.
Participants with a confirmed diagnosis of ALS per Gold Coast criteria as determined by a neurologist specializing in ALS (e.g., the site principal investigator or sub-investigator for this study).
Participant is able to daily consume up to 240 mL of the investigational drug suspension without substantial dysphagia, OR can intake the investigational product through a gastrostomy tube.

Exclusion Criteria:
Participant is eligible for participation in: (i) the HEALEY ALS Platform trial (NCT04297683), or (ii) any active study investigating CNM-Au8 for the treatment of ALS.
Participant has a history of any clinically significant or unstable medical condition (other than ALS) that may interfere with assessment of safety or compromise the study objectives.
Based on the investigator’s judgment, participants who may have difficulty complying with the protocol and/or any study procedures.
Within the prior 90-days the participant has had clinically significant findings on standard hepatic, hematologic, or renal safety assays.
Participant is currently involved in another placebo-controlled clinical trial (note: concomitant therapy with other investigational products is permitted with certain restrictions—see concomitant medications section below).
Neurology
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Understanding the Well-being of Advanced Counseling Students of Color

The primary objective of this study is to increase our understanding of the ways in which perceived discrimination, coping strategies, competence, stress, social support, and self-efficacy in counselor education programs relate to overall well-being for advanced counseling students of color.

No
 

Kyesha Isadore
Kyesha Isadore - at kmi5@psu.edu or 337-326-3788
Counselor Education, Counseling Psychology, and Rehabilitation Service (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00014713
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Currently enrolled as a master’s or doctoral student in a counseling education program
18 years of age or older
Capable of providing informed consent without the assistance of a legal guardian
Identify as a racial or ethnic minority
Able to understand written and spoken English at the time of the survey

Exclusion Criteria:
Adults unable to consent
Individuals who are not yet adults (infants, children, teenagers)
Education, Mental & Behavioral Health
I'm interested
Share via email

A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open-Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC).

this is a phase II study to evaluate the safety and tolerability of 2 doses of elafibranor in participants with Primary Sclerosing Cholangitis (PSC), and its potential effect on the change in serum alkaline phosphatase (ALP) and other hepatic markers of PSC during 12 weeks of treatment in the double-blind period (DBP) compared to placebo. This will be followed by a 96-week open-label extension (OLE) period (no placebo) to assess long-term safety and maintenance of effects of elafibranor.After the first dose of the study intervention on Day 1, the participants will have study visits every 4 weeks through Week 12 of the DBP to assess efficacy and safety. In the OLE period, the study visits for each participant will occur after 4 weeks of entering the OLE, then every 12 weeks up to Week 52, followed by every 22 weeks up to Week 96 which will be the end of treatment (EOT). All participants will have a safety follow-up 4 weeks after the last dose of study intervention.

There will be 2 screening visits followed by 4 visits during the double blind/placebo part of the trial, followed by visits every 3 months for the open label part of the study. All visits will be in person. Blood will be drawn at every visit. Urine will be collected at most visits. ECG's (recording of your heart activity) will be done on a regular basis. Additional procedures include fibroscans (scan of your liver to determine liver stiffness) and ultrasound exams of your abdomen and bladder. Multiple questionnaires will be competed throughout the trial period.

Yes
 

Karen Krok
Laurie Peiffer - at lpeiffer@pennstatehealth.psu.edu or 717-531-5226
Medicine: Gastroenterology and Hepatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05627362
STUDY00021989
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of PSC
Elevated ALP

Exclusion Criteria:
Chronic Liver Disease
percutaneous drain or bile duct stent
cholangiocarcinoma
bacterial cholangitis within 60 days
hepatic decompensation
Digestive Systems & Liver Disease
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

This Phase 1 and 2 study is to determine the safety of APL-101 in subjects with NSCLC with specific mutations. It is also to determine the dose that is tolerable for oral administration of APL-101. And to see if there is a clinical benefit to subjects for the amount of time to progression, or progression free survival and overall survival.

We are asking you to give permission for your doctor to send your stored tumor tissue sample for cancer genetic analysis. As part of your cancer care, your doctor may have already collected a tumor tissue biopsy sample (of your cancer tissue) in the past, recently, or being planned as part of standard medical care. Your doctor will ask for any of your stored or available tumor tissue sample collected elsewhere from previous doctors you may have seen in the past. We will not ask you to undergo a new tissue biopsy procedure for this testing however your treating physician may decide to do so as part of your standard of care.There is no required visit for this testing. Once you have signed this consent, your available tumor tissue sample from a prior biopsy or surgery along with the pathology report will be sent to an accredited and certified external genetic laboratory (such as Caris Life Sciences or Interpace Pharma Solutions) to test and understand your cancer’s genetic make-up. The use of your tumor tissue samples as described in this form is necessary for the genetic testing. Without your consent to test your samples, the genetic testing cannot be performed. Once you agree to provide your samples, they cannot be returned to your doctor’s clinic. If the genetic testing of your samples show you have c-MET genetic dysregulations in your cancer, your doctor will discuss your treatment options including clinical trials, such as the APL-101-01 SPARTA trial, with you. If you are interested in participating, you will be asked to review and sign another participant information and informed consent form for the clinical trial before undergoing further screening tests to confirm if you are eligible to participate. The genetic results could also be used to help your clinic doctor decide on an approved therapy, or other investigational therapies that may be right for your specific cancer genetic alterations.

Yes
 

Patrick Ma
Irina Geier - at igeier@pennstatehealth.psu.edu or 717-531-8678
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03175224
STUDY00014799
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Phase 1, histologically and / or cytological confirmed unresectable or metastatic solid malignancy, refractory to standard therapies with no more than three prior lines of therapy
Women of child-bearing potential (WOCBP) must have a negative serum or β-human chorionic gonadotropin (β-hCG) at screening or evidence of surgical sterility or evidence of postmenopausal status.
Abnormal c-Met dysregulation, by tissue and/or plasma, defined as the following from local/archival molecular pre-screening evaluations.
Measurable disease according to RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0–1

Exclusion Criteria:
Hypersensitivity to APL-101, excipients of the drug product, or other components of the study treatment regimen.
Known mutation/gene rearrangement of EGFR (except for Cohort C), ALK, ROS1, RET, NTRK, KRAS, and BRAF.
Active uncontrolled systemic bacterial, viral, or fungal infection or clinically significant, active disease process
History of, or currently, or at risk for, cardiac disease (e.g., long QT syndrome [> 450 msec QTcF or concurrent treatment with any medication that prolongs QT interval).
Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter drug absorption (e.g., Crohn’s, ulcerative colitis, active inflammatory bowel disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption sydrome).
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI 23-145 Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

This trial is comparing two different therapies for the treatment of newly diagnosed multiple myeloma who are not having a bone marrow transplant.

Subjects will be required to keep all research visits, take medications as directed, report any new medication of side effects to the study team,

Yes
 

Kevin Rakszawski
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04566328
STUDY00024221
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patient must have suspected or confirmed newly diagnosed multiple myeloma (MM) by International Myeloma Working Group (IMWG) criteria and must not have received more than one cycle of treatment.
Patient must be considered ineligible for autologous stem cell transplantation by the treating physician, or willing to delay stem cell transplantion until first relapse or later.
Patient must agree to register to the mandatory Celgene Revlimid REMS program and be willing and able to comply with the requirements of the Revlimid REMS program.
Patient must have standard risk MM as defined by the Revised International Staging System (R-ISS) Stage I or II.31
Patient must be able to undergo diagnostic bone marrow aspirate following preregistration if not performed previously.

Exclusion Criteria:
Patient must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
Patient must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
Patient must not have moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification.
Patient may have a history of current or previous deep vein thrombosis (DVT) or pulmonary embolism (PE) but must be willing to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation.
Patient must not have peripheral neuropathy ≥ Grade 2 on clinical examination or grade 1 with pain
Cancer
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 3 locations

Study Locations

Hide all locations
Location Contacts
Harrisburg, PA ,
Hershey, PA ,
Reading, PA ,

Testing the effect of ENDS flavors on Neurotransmission

Tobacco users will be randomized to use electronic cigarettes containing varying levels of nicotine and flavor during laboratory protocols to investigate the effects on the brain and behavior. Subjects will complete surveys, functional magnetic resonance imaging scans, and complete computerized tasks. Eligible participants include daily users of inhaled tobacco products who are at least 21 years old, able to read and write in English, and not planning to quit tobacco use within the next month. Exclusion criteria include: current substance use impairing participation, unstable or significant medical conditions, current use of smoking cessation medication, uncontrolled serious mental illness, and MRI safety or neurological contraindications.

Subjects will taste test a variety of e-cigarette flavorings, answer questions and complete a single MRI.

50

Yes
 

Andrea Hobkirk
Kenneth Houser - at abl@pennstatehealth.psu.edu or 717-531-5473
Psychiatry and Behavioral Health (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT05836051
STUDY00019883
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Daily inhaled nicotine user for over 1 year
No plan to quit tobacco use in the next month
Age 21 or older
Able to read and write in English

Exclusion Criteria:
MRI Contraindications
Unstable or Significant Medical Conditions
Uncontrolled serious mental illness
Current substance abuse
Smoking, Vaping, Nicotine and Tobacco, Addiction & Substance Abuse, Mental & Behavioral Health
Prefer not to display
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI# 18-127 EA6174 Adjuvant MK-3475 to SOC

The purpose of this Phase III study is to compare Overall Survival (OS) and Recurrence Free Survival (RFS) across the two arms: MK3475 (Pembrolizumab) to Standard of Care Observation. Patients will undergo standard clinical procedures including physical, labs, vitals, ecg's, and imaging.

We are asking you to take part in a research study. We do research studies to try to answer questions about how to prevent, diagnose, and treat diseases like cancer.

Yes
 

Joseph Drabick
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03712605
SITE00000461
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patients must have an ECOG performance Status: 0, 1, or 2
Patient must have a histological confirmation of diagnosis of Merkel cell carcinoma (MCC), pathologic stages (AJCC version 8) I-IIIb.
completely resected by surgery within 8 weeks before enrollment.
All patients must have disease-free status documented by a complete physical examination and conventional imaging studies within 4 weeks prior to randomization.
Patients must not be on active immunosuppression, have a history of life threating virus, have had other cancer diagnoses in the last two years

Exclusion Criteria:
Women who are pregnant
present metastases
previous systemic therapy or radiation therapy for Merkel cell carcinoma.
inoperable disease who have received radiation are not eligible.
history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

The opioid epidemic among Pennsylvania immigrants: Insights from prescribers and rehabilitation professionals

We will interview prescribers and rehabilitation professionals who have provided services and treatment to immigrants in PA with a history of opioid abuse. The goal is to highlight best practices, resources needed, cultural awareness, and training needs to support the rehabilitation and recovery of this client group.

One 45-minute, recorded interview via Zoom

$50.00 Amazon gift card

No
 

Abigail Akande
Abigail Akande - at aoa29@psu.edu
Social and Behavioral Sciences (ABINGTON)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00021288
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Medication Assisted Treatment Provider
Substance abuse treatment provider
Opiate pain medication prescriber
Service provider in PA
Provide services to immigrants (non-citizens)

Exclusion Criteria:
Working outside of PA
No experience with immigrant patients/clients
No experience with opioid use disorder
Addiction & Substance Abuse, Mental & Behavioral Health
Not applicable
I'm interested
Share via email

Impact of fermented pulses on inflammation and the gut microbiota

The purpose of this study is to investigate whether fermenting pulse foods (e.g. beans, chickpeas, lentils, peas, etc.) changes their effects on the gut microbiome and inflammation. Participants will eat provided meals of either fermented or unfermented pulses, providing blood and fecal samples at the beginning of the study and after two weeks of eating meals containing each of the pulse types.

The study lasts 8 weeks. 2 weeks where you do not consume any of the test food (pulses such as chickpeas, lentils, peas or beans), 2 weeks of consuming the first type of the provided meals, 2 weeks without consuming any of the test foods, 2 weeks consuming the second type of provided meals. There will be five in person visits, one at the beginning to provide consent and then one at the end of each 2 week section. At three of these visits a fecal sample will be collected, blood will be drawn and a dietary survey completed.

300

Yes
 

Darrell Cockburn
Darrell Cockburn - at dwc30@psu.edu or 814-863-2950
Food Science (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT06134076
STUDY00023162
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
healthy
18-65

Exclusion Criteria:
antibiotic use in the past month
BMI >24.9
Taking any medication for diabetes or weight management
Pregnant
Allergies to meal components
Food & Nutrition
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON)

This is a phase 2b clinical trial looking to see if the drug PLN-74809 (bexotegrast) is effective and safe in patients diagnosed with idiopathic pulmonary fibrosis (IPF).

If you choose to participate in this study and meet all the study entry requirements, you will be randomly assigned (by chance; like the flip of a coin) to receive either bexotegrast or placebo for the whole study. Neither your study doctor nor you will know whether you are receiving bexotegrast or placebo. You will be required to visit the Hershey Medical Center on at least 8 separate occasions over an approximate 58-week period. Procedures that will be performed during your visits include, but are not limited to, physical exams, blood tests, ECGs, completing questionnaires, lung functions tests, and CT scans.

1200

Yes
 

Rebecca Bascom
Timothy Sheehan - at tsheehan@pennstatehealth.psu.edu or 717-531-2925
Medicine: Pulmonary, Allergy and Critical Care (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06097260
STUDY00023219
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
>/= 40 years of age
IPF diagnosis ≤ 7 years prior to screening
If on Ofev or Esbriet, must be on stable dose for >/= 12 weeks
FVC >/=45% predicted
DLCO >/= 30% predicted and </= 90% predicted

Exclusion Criteria:
Taking medication for pulmonary hypertension
Obstructive lung disease
Current smokers
Active infection
IPF exacerbation within the last 6 months
Lung Disease & Asthma
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,